AI Insight: Astrana Health’s current price aligns closely with its fair value, reflecting minimal implied upside (0.2%), although valuation methods vary widely—from high DCF estimates to low P/E valuations. Financial health shows strong growth but weak profitability and efficiency, contributing to high volatility (65% coefficient of variation) and 30.6% downside risk. Monte Carlo scenarios indicate a broad value range ($31–$281), signaling significant uncertainty alongside potential high reward.